To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.

H.R. 9635 of the 119th Congress, introduced on July 9, 2026, aims to amend the Federal Food, Drug, and Cosmetic Act to create specific regulations ensuring the ongoing evaluation of human drug and device submissions in the event of a funding gap.